M
Mark Wunderlich
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 82
Citations - 6627
Mark Wunderlich is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 27, co-authored 63 publications receiving 4968 citations. Previous affiliations of Mark Wunderlich include Hospital Research Foundation.
Papers
More filters
Journal ArticleDOI
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber,Junwei Shi,Junwei Shi,Eric Wang,Amy R. Rappaport,Amy R. Rappaport,Harald Herrmann,Edward Allan R. Sison,Daniel Magoon,Jun Qi,Katharina Blatt,Mark Wunderlich,Meredith J. Taylor,Christopher Johns,Agustin Chicas,James C. Mulloy,Scott C. Kogan,Patrick Brown,Peter Valent,James E. Bradner,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Christopher R. Vakoc +23 more
TL;DR: The results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.
Journal ArticleDOI
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Rui Su,Lei Dong,Chenying Li,Sigrid Nachtergaele,Mark Wunderlich,Ying Qing,Xiaolan Deng,Yungui Wang,Yungui Wang,Xiaocheng Weng,Chao Hu,Chao Hu,Mengxia Yu,Jennifer R. Skibbe,Qing Dai,Dongling Zou,Tong Wu,Kangkang Yu,Hengyou Weng,Huilin Huang,Kyle Ferchen,Xi Qin,Bin Zhang,Jun Qi,Atsuo T. Sasaki,David R. Plas,James E. Bradner,Minjie Wei,Guido Marcucci,Xi Jiang,James C. Mulloy,Jie Jin,Chuan He,Jianjun Chen,Jianjun Chen +34 more
TL;DR: While R-2HG accumulated in IDH1/2 mutant cancers contributes to cancer initiation, this work demonstrates anti-tumor effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via targeting FTO/m6A/MYC/CEBPA signaling.
Journal ArticleDOI
METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification
Hengyou Weng,Huilin Huang,Huizhe Wu,Xi Qin,Boxuan Simen Zhao,Lei Dong,Hailing Shi,Jennifer R. Skibbe,Chao Shen,Chao Hu,Chao Hu,Yue Sheng,Yungui Wang,Yungui Wang,Mark Wunderlich,Bin Zhang,Louis C. Dore,Rui Su,Xiaolan Deng,Xiaolan Deng,Kyle Ferchen,Chenying Li,Chenying Li,Miao Sun,Zhike Lu,Xi Jiang,Guido Marcucci,James C. Mulloy,Jian-Hua Yang,Zhijian Qian,Minjie Wei,Chuan He,Jianjun Chen +32 more
TL;DR: The results reveal the SPI1-METTL14-MYB/MYC signaling axis in myelopoiesis and leukemogenesis and highlight the critical roles of METTL14 and m6A modification in normal and malignant hematopoiedis.
Journal ArticleDOI
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.
Yue Huang,Rui Su,Yue Sheng,Lei Dong,Lei Dong,Ze Dong,Hongjiao Xu,Tengfeng Ni,Zijie Scott Zhang,Zhang Tao,Chenying Li,Li Han,Zhen-Yun Zhu,Fulin Lian,Jiangbo Wei,Qiangqiang Deng,Yungui Wang,Mark Wunderlich,Zhiwei Gao,Guoyu Pan,Dafang Zhong,Hu Zhou,Naixia Zhang,Jianhua Gan,Hualiang Jiang,James C. Mulloy,Zhijian Qian,Zhijian Qian,Jianjun Chen,Jianjun Chen,Cai-Guang Yang +30 more
TL;DR: Two promising FTO inhibitors are developed, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's m6A demethylase activity, suggesting that FTO is a druggable target and that targeting FTO by small-molecule inhibitors holds potential to treat AML.
Journal ArticleDOI
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
Mark Wunderlich,Fu-Sheng Chou,Kevin A. Link,Benjamin Mizukawa,Perry Rl,Martin Carroll,James C. Mulloy +6 more
TL;DR: AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.